GB202110403D0 - Ulodesine Salt - Google Patents

Ulodesine Salt

Info

Publication number
GB202110403D0
GB202110403D0 GBGB2110403.9A GB202110403A GB202110403D0 GB 202110403 D0 GB202110403 D0 GB 202110403D0 GB 202110403 A GB202110403 A GB 202110403A GB 202110403 D0 GB202110403 D0 GB 202110403D0
Authority
GB
United Kingdom
Prior art keywords
ulodesine
salt
ulodesine salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2110403.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laevoroc Immunology
Original Assignee
Laevoroc Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laevoroc Immunology filed Critical Laevoroc Immunology
Priority to GBGB2110403.9A priority Critical patent/GB202110403D0/en
Publication of GB202110403D0 publication Critical patent/GB202110403D0/en
Priority to EP22754840.1A priority patent/EP4373579A1/en
Priority to KR1020247005390A priority patent/KR20240038017A/ko
Priority to PCT/EP2022/070369 priority patent/WO2023001893A1/en
Priority to CA3226849A priority patent/CA3226849A1/en
Priority to CN202280050721.6A priority patent/CN117897383A/zh
Priority to AU2022314207A priority patent/AU2022314207A1/en
Priority to MX2024000936A priority patent/MX2024000936A/es
Priority to JP2024503814A priority patent/JP2024525254A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB2110403.9A 2021-07-20 2021-07-20 Ulodesine Salt Ceased GB202110403D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB2110403.9A GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt
EP22754840.1A EP4373579A1 (en) 2021-07-20 2022-07-20 Ulodesine salt
KR1020247005390A KR20240038017A (ko) 2021-07-20 2022-07-20 울로데신 염
PCT/EP2022/070369 WO2023001893A1 (en) 2021-07-20 2022-07-20 Ulodesine salt
CA3226849A CA3226849A1 (en) 2021-07-20 2022-07-20 Ulodesine salt
CN202280050721.6A CN117897383A (zh) 2021-07-20 2022-07-20 乌洛地辛盐
AU2022314207A AU2022314207A1 (en) 2021-07-20 2022-07-20 Ulodesine salt
MX2024000936A MX2024000936A (es) 2021-07-20 2022-07-20 Sal de ulodesina.
JP2024503814A JP2024525254A (ja) 2021-07-20 2022-07-20 ウロデシン塩

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2110403.9A GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt

Publications (1)

Publication Number Publication Date
GB202110403D0 true GB202110403D0 (en) 2021-09-01

Family

ID=77443478

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2110403.9A Ceased GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt

Country Status (9)

Country Link
EP (1) EP4373579A1 (https=)
JP (1) JP2024525254A (https=)
KR (1) KR20240038017A (https=)
CN (1) CN117897383A (https=)
AU (1) AU2022314207A1 (https=)
CA (1) CA3226849A1 (https=)
GB (1) GB202110403D0 (https=)
MX (1) MX2024000936A (https=)
WO (1) WO2023001893A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
NZ595590A (en) * 2009-03-24 2013-11-29 Biocryst Pharm Inc Useful pharmaceutical salts of 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one

Also Published As

Publication number Publication date
CA3226849A1 (en) 2023-01-26
CN117897383A (zh) 2024-04-16
EP4373579A1 (en) 2024-05-29
JP2024525254A (ja) 2024-07-11
KR20240038017A (ko) 2024-03-22
AU2022314207A1 (en) 2024-01-18
WO2023001893A4 (en) 2023-03-30
WO2023001893A1 (en) 2023-01-26
MX2024000936A (es) 2024-06-19

Similar Documents

Publication Publication Date Title
IL290692A (en) Salt
CA196956S (en) Onesie
IL299294A (en) tyk-2 inhibitor
ZA202107474B (en) Sulcardine salts
GB202207709D0 (en) 5-chiloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt
GB202110403D0 (en) Ulodesine Salt
IL304419A (en) salt crystals
GB202104272D0 (en) Salt
GB202004504D0 (en) Salt
GB201809460D0 (en) Salt form
GB201809458D0 (en) Salt form
GB201904190D0 (en) Salt
HK40114030A (en) Ulodesine salt
GB202113569D0 (en) Disclosure
GB202113199D0 (en) Disclosure
GB202110620D0 (en) Disclosure
GB202109778D0 (en) Disclosure
GB202109650D0 (en) Disclosure
GB202109237D0 (en) Disclosure
DK4124060T3 (en) Høreapparat
HK40075942A (en) Salt
CA204055S (en) Spiralizer
GB202101495D0 (en) Disclosure
GB202101496D0 (en) Disclosure
GB202100931D0 (en) Disclosure

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)